11.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$11.10
Aprire:
$11.14
Volume 24 ore:
10.29M
Relative Volume:
2.12
Capitalizzazione di mercato:
$992.16M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-4.2973
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+1.64%
1M Prestazione:
-0.36%
6M Prestazione:
+40.71%
1 anno Prestazione:
+57.20%
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta VERV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VERV
Verve Therapeutics Inc
|
11.13 | 989.58M | 20.65M | -192.65M | -134.39M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2024-04-08 | Iniziato | H.C. Wainwright | Buy |
2023-04-13 | Iniziato | Canaccord Genuity | Buy |
2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
2022-12-15 | Iniziato | Goldman | Sell |
2022-10-06 | Iniziato | Credit Suisse | Neutral |
2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
2021-09-24 | Iniziato | Stifel | Hold |
2021-07-12 | Iniziato | Guggenheim | Buy |
2021-07-12 | Iniziato | JP Morgan | Neutral |
2021-07-12 | Iniziato | Jefferies | Buy |
2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Lilly completes tender offer for Verve Therapeutics shares - Investing.com
Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly
Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan
Verve Therapeutics Inc. Stock Analysis and ForecastRapid portfolio appreciation - Autocar Professional
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - MSN
What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN
Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex
What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com
Is Verve Therapeutics Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com
(VERV) Trading Advice - news.stocktradersdaily.com
3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru
Lilly’s $1 billion CRISPR bet: what Verve means for gene editing - The Pharma Letter
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada
Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa
Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks
Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN
Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):